ONO 4817 (Synonyms: MMP Inhibitor V) |
Katalog-Nr.GC15005
One-Click Copy Product Info
|
An inhibitor of MMP-2 and MMP-9
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 223472-31-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ONO 4817 is a potent inhibitor of MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-13 with IC50 value of 0.73 nM, 42 nM, 2500 nM, 1.1 nM, 2.1 nM, 0.45 nM and 1.1 nM, respectively [1].
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that belong to the metzincin superfamily and play an important role in tissue remodeling associated with various physiological or pathological processes such as morphogenesis, angiogenesis, tissue repair, cirrhosis, arthritis, and metastasis. It has been reported that MMPs involve in the tumor invasion and angiogenesis processes [1].
ONO 4817 is a potent MMP inhibitor and has a quite spread spectrum on MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-13, while has no effect on MMP-1 . When tested with the supernatant of lung cancer cell line PCI14PE6 cells, ONO 4817 caused the inhibition on the activities of MMP-2 and MMP-9 in a dose dependent manner (0.1-10 μM) [2].
In nude mice model with PC14 or PC14PE6 subcutaneous xenograft that produced metastasis only in the lungs, administration of ONO 4817 caused significant reduction of the number of lung metastasis, inhibited the formation of pleural effusion and decreased the tumor volumes [2]. In Sprague-Dawley rat model, ONO 4817 treatment (5 mg) significantly inhibited thickening of the submesothelial layer and accumulation of type I collagen in the peritoneum and prevented the increase of the number of macrophages and blood vessels [3].
References:
[1]. Okamoto, Y., et al., A matrix metalloproteinase inhibitor, ONO-4817, suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit. Int Heart J, 2007. 48(3): p. 369-78.
[2]. Shiraga, M., et al., Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res, 2002. 62(20): p. 5967-73.
[3]. Ro, Y., et al., Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant, 2007. 22(10): p. 2838-48.
| Cas No. | 223472-31-9 | SDF | |
| Überlieferungen | MMP Inhibitor V | ||
| Chemical Name | N-[1-(ethoxymethoxy)-5-(hydroxyamino)-4-methyl-5-oxopentan-2-yl]-4-phenoxybenzamide | ||
| Canonical SMILES | CCOCOCC(CC(C)C(=O)NO)NC(=O)C1=CC=C(C=C1)OC2=CC=CC=C2 | ||
| Formula | C22H28N2O6 | M.Wt | 416.47 |
| Löslichkeit | <20.82mg/ml in ethanol; <41.65mg/ml in DMSO | Storage | Store at RT |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4011 mL | 12.0057 mL | 24.0113 mL |
| 5 mM | 480.2 μL | 2.4011 mL | 4.8023 mL |
| 10 mM | 240.1 μL | 1.2006 mL | 2.4011 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)